39911-99-4

Basic information

• Product Name: ethyl 4-(morpholin-4-yl)phenylacetate
• Synonyms: ethyl 4-(morpholin-4-yl)phenylacetate
• CAS NO: 39911-99-4
• Molecular Weight: 249.31
• Mol File: 39911-99-4.mol
• Article Data: 10

Chemical Properties

• CAS DataBase Reference: ethyl 4-(morpholin-4-yl)phenylacetate(CAS DataBase Reference)
• NIST Chemistry Reference: ethyl 4-(morpholin-4-yl)phenylacetate(39911-99-4)
• EPA Substance Registry System: ethyl 4-(morpholin-4-yl)phenylacetate(39911-99-4)

Safety Data

• Hazardous Substances Data: 39911-99-4(Hazardous Substances Data)

Upstream product

• 30483-75-1 4-bromophenyl-morpholine 
• 105-53-3 diethyl malonate 
• 373361-46-7 ethyl 2-[4-(4-morpholinyl)phenyl]-2-oxoacetate 
• 7440-44-0 pyrographite 
• 110-91-8 morpholine 
• 14062-25-0 Ethyl 4-bromophenylacetate 

Downstream Products

• 26577-57-1 4-(morpholin-4-yl)phenylacetic acid 
• 1450907-93-3 C₂₁H₃₃N₃O₅ 
• 1450907-83-1 C₂₅H₃₁NO₅ 
• 1450907-82-0 C₂₁H₂₁N₃O 
• 373361-47-8 2-[4-(4-morpholinyl)phenyl]acetyl chloride 

Relevant articles and documents

Copper-Catalyzed Ullmann-Type Coupling and Decarboxylation Cascade of Arylhalides with Malonates to Access α-Aryl Esters

We have developed a high-efficiency and practical Cu-catalyzed cross-coupling to directly construct versatile α-aryl-esters by utilizing readily available aryl bromides (or chlorides) and malonates. These gram-scale approaches occur with turnovers of up to 1560 and are smoothly conducted by the usage of a low catalyst loading, a new available ligand, and a green solvent. A variety of functional groups are tolerated, and the application occurs with α-aryl-esters to access nonsteroidal anti-inflammatory drugs (NSAIDs) on the gram scale.

Cobalt Catalysis for Enantioselective Cyclobutanone Construction

Over the past 40 years, intramolecular hydroacylation has favored five-membered rings, in preference to four membered rings. Herein, we report a catalyst derived from earth-abundant cobalt that enables preparation of cyclobutanones, with excellent regio-,

COMPOUNDS AND THEIR METHODS OF USE

Compounds and compositions comprising compounds that inhibit glutaminase are described herein. Also described herein are methods of using the compounds that inhibit glutaminase in the treatment of cancer.